Genetic risk of Parkinson disease and progression:
An analysis of 13 longitudinal cohorts
Citation Manager Formats
Make Comment
See Comments
This article has a correction. Please see:

Article Information
- Received November 13, 2018
- Accepted in final form April 30, 2019
- First Published July 9, 2019.
Author Disclosures
- Hirotaka Iwaki, MD,
- Cornelis Blauwendraat, PhD,
- Hampton L. Leonard, MS,
- Ganqiang Liu, PhD,
- Jodi Maple-Grødem, PhD,
- Jean-Christophe Corvol, MD, PhD,
- Lasse Pihlstrøm, MD, PhD,
- Marlies van Nimwegen, PhD,
- Samantha J. Hutten, PhD,
- Khanh-Dung H. Nguyen, PhD,
- Jacqueline Rick, PhD,
- Shirley Eberly, MS,
- Faraz Faghri, MS,
- Peggy Auinger, MS,
- Kirsten M. Scott, MRCP, MPhil,
- Ruwani Wijeyekoon, MRCP,
- Vivianna M. Van Deerlin, MD, PhD,
- Dena G. Hernandez, PhD,
- Aaron G. Day-Williams, PhD,
- Alexis Brice, MD,
- Guido Alves, MD, PhD,
- Alastair J. Noyce, MRCP, PhD,
- Ole-Bjørn Tysnes, MD, PhD,
- Jonathan R. Evans, MRCP, PhD,
- David P. Breen, MRCP, PhD,
- Karol Estrada, PhD,
- Claire E. Wegel, MPH,
- Fabrice Danjou, MD, PhD,
- David K. Simon, MD, PhD,
- Bernard Ravina, MD,
- Mathias Toft, MD, PhD,
- Peter Heutink, PhD,
- Bastiaan R. Bloem, MD, PhD,
- Daniel Weintraub, MD,
- Roger A. Barker, MRCP, PhD,
- Caroline H. Williams-Gray, MRCP, PhD,
- Bart P. van de Warrenburg, MD, PhD,
- Jacobus J. Van Hilten, MD, PhD,
- Clemens R. Scherzer, MD,
- Andrew B. Singleton, PhD and
- Mike A. Nalls, PhD
- Hirotaka Iwaki, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
The Michael J. Fox Foundation for Parkinson's Research
NONE
NONE
NONE
NONE
NONE
NONE
- Cornelis Blauwendraat, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hampton L. Leonard, MS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ganqiang Liu, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jodi Maple-Grødem, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Norwegian Parkinson's Association (Norges Parkinsonforbund) The Norwegian association for public health (Nasjonalforeningen for folkehelsen)
NONE
NONE
NONE
NONE
NONE
NONE
- Jean-Christophe Corvol, MD, PhD,
Advisory board for Pfizer, Theranexus, Zambon, and BMS
NONE
Speaker honoraria from Zambon, travel grant from Zambon and Abbvie
Movement Disorders journal, associate editor, 2015
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Research grant from Actelion
Grants from the French Ministry of Health, ANR
NONE
Grant from the Michael J Fox Foundation, France Parkinson Stock/Stock Options, Medical Equipment & Materials: Stock option in B&A Therapeutics
NONE
NONE
NONE
NONE
NONE
NONE
- Lasse Pihlstrøm, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Southeastern Norway Regional Health Authority, project leader, PhD-grant, 2017-current
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marlies van Nimwegen, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Samantha J. Hutten, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Khanh-Dung H. Nguyen, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Biogen, Scientist, 3 years (2015-2018, where my involvement with this work is linked to)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jacqueline Rick, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Shirley Eberly, MS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1) Commercial entity: Voyager Pharmaceuticals 2) Commercial entity: TevaPharmaceuticals 3) Commercial entity: Vaccinex
1) NIH 5 U01 NS080840-05 Holloway 04/01/14 ? 03/31/19 Data Coordination Center for STEADY-PD3. Data analysis. 2) NIH 5 U01 NS089666-03 Oakes 09/01/15 ? 06/30/20 Phase 3 Trial of Inosine for Parkinson?s Disease - DCC. Data analysis.
NONE
Michael J Fox Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Faraz Faghri, MS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) National Institute on Aging, National Institutes of Health
NONE
NONE
NONE
NONE
NONE
(1) Mayo Clinic
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Peggy Auinger, MS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kirsten M. Scott, MRCP, MPhil,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Wellcome Trust Clinical PhD Fellowship 106565/Z/14/Z
NONE
NONE
NONE
NONE
NONE
NONE
- Ruwani Wijeyekoon, MRCP,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Vivianna M. Van Deerlin, MD, PhD,
NONE
NONE
NONE
Member, Editorial Board,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Merck
NIH AG010124 NIH AG017586 NIH AG032953 NIH R01-NS94003 NIH R21-AG046499 NIH SBIR R44NS089423
Penn Center for Precision Medicine
ALS Association
NONE
NONE
NONE
NONE
NONE
NONE
- Dena G. Hernandez, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Government employee NIH Biologist
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Aaron G. Day-Williams, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Biogen, Associate Director, 2/15-11/16 Merck, Director, 12/16 - 7/18 Flagship Labs 60 Inc., Vice President, 8/18-Present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Alexis Brice, MD,
(1) FWO (Research Foundation Flanders) (2) ERC (European Research Council) (3) BMBF (Bundesministeriums f?r Bildung and Forschung-Berlin Germany)
NONE
Conference honorarium Tokyo, Sumitomo Dainippon Pharma Consulting honorarium, Sanofi, France
(1)Neurology and Clinical Neuroscience, Editorial Board Member, 2012-(2)Parkinsonism and Related Disorders,Editorial Board Member,2008-(3)Brain,Editorial Board Member,2007-(4)Neurodegenerative Diseases, Editorial Board Member, 2003-(5) The Cerebellum, Editorial Board Member, 2001-(6) Neurogenetics, Editorial Board Member, 2001-
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Grants from French Research Agency, EU
NONE
(1)France Parkinson Association, (2) Roger de Spoelberch Foundation (ref. R12123DD), (3)ARN (Agence nationale pour la Recherche)
NONE
NONE
NONE
NONE
NONE
NONE
- Guido Alves, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)Norwegian Parkinson's disease Association
NONE
NONE
NONE
NONE
NONE
NONE
- Alastair J. Noyce, MRCP, PhD,
Britannia Pharmaceuticals
NONE
Profile Pharmaceuticals
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Parkinson's UK Virginia Kieley Benefaction
NONE
NONE
NONE
NONE
NONE
NONE
- Ole-Bjørn Tysnes, MD, PhD,
NONE
NONE
Given lectures for several pharmaceutical companies
Acta Neurologica Scandinavica. More than 10 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jonathan R. Evans, MRCP, PhD,
1) UCB Pharma 2)Global Kinetics Limited 3)Britannia Pharmaceuticals 4)AbbVie pharmaceuticals
NONE
(1) UCB pharma: speaker honoraria, (2) Britannia pharmaceuticals: travel and conference fees (3) AbbVie pharamceuticals: honoraria, travel and conference fees (4) Ipsen Pharmaceuticals: travel and conference fees
NONE
NONE
NONE
NONE
(1) Glaxo-Smithkline
1) UCB pharma 2)Britannia Pharmaceuticals 3)AbbVie pharamceuticals 4)Global Kinetics
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David P. Breen, MRCP, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Wellcome Clinical Research Career Development Fellowship, (2) Edmond J. Safra Foundation via the Michael J. Fox Foundation, (3) Rowling Scholarship from the Anne Rowling Regenerative Neurology Clinic, University of Edinburgh
NONE
NONE
NONE
NONE
NONE
NONE
- Karol Estrada, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Former employee of Biogen (3 years) Current employee of Biomarin (6 months)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Claire E. Wegel, MPH,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Michael J Fox Foundation for Parkinson's Disease Research, The Foundation for Peripheral Neuropathy
NONE
NONE
NONE
NONE
NONE
NONE
- Fabrice Danjou, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David K. Simon, MD, PhD,
(1) Scientific Advisory Board for the Weston Brain Institute (non-profit) (2) Linked Clinical Trials Committee; Cure Parkinson's Trust (non-profit) (3) Steering Committee for phase 2 clinical trial of Nilotinib in Parkinson's disease; The Michael J Fox Foundation (non-profit) (4) Steering Committee for the
NONE
(1) Parkinson Study Group Executive Committee member (non-profit); travel expenses paid for attending the annual meeting. (2) Steering Committee for the
NONE
NONE
NONE
NONE
(1) Lysosomal Therapeutics, Inc (commercial); consultant for clinical product development (2) Cerevance, Inc. (commercial); Consultant for clinical trial
NONE
NONE
NONE
(1) Research grant to fund clinical research study from Lysosomal Therapeutics (2) Research grant to fund clinical study from BioElectron Technologies (3) Laboratory research grant (Mission Therapeutics; Commercial)
(1) National Institutes of Health (NINDS); 1R01NS086352; PI; 2014 - 2019 (2) National Institutes of Health (NINDS); 1R21NS094840; PI; 2017 - 2019 (3) National Institutes of Health (NINDS); 1P50NS094733; Outreach Coordinator; 2015 - 2020 (4) National Institutes of Health (NINDS); subcontract from Massachusetts General Hospital; site PI (SURE-PD3 clinical trial); 2016 - 2019
NONE
(1) Weston Brain Institute Advisor Fellowship (2) National Parkinson Foundation Community Grant Award for wellness programs
NONE
NONE
NONE
NONE
NONE
NONE
- Bernard Ravina, MD,
Commercial: Voyager Therapeutics Non Profit: Michael J Fox Foundation
NONE
NONE
NONE
NONE
NONE
Voyager Therapeutics and Praxis Precision Medicine
NONE
NONE
NONE
NONE
NONE
NIH, DOD, Michael J Fox Foundation
NONE
Michael J Fox Foundation
Commercial - Voyager Therapeutics and Praxis Precision Medicine
NONE
NONE
NONE
NONE
NONE
- Mathias Toft, MD, PhD,
NONE
NONE
Speaker honoraria from Roche.
Editorial board member of PLOS One, Frontiers Neurology, Case Reports in Neurological Medicine
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Research grants from the Research Council of Norway, Regional Health Authority South-Eastern Norway
NONE
Research grants from the Michael J. Fox Foundation, Norwegian Parkinson Research Fund
NONE
NONE
NONE
NONE
NONE
NONE
- Peter Heutink, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Commercial entity Neuron23 LLC
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bastiaan R. Bloem, MD, PhD,
(1) Michael J Fox Foundation (non-profit entity); (2) Parkinson Vereniging (non-profit entity); (3) Movement Disorder Society (non-profit entity); (4) Brian Grant Foundation (non-profit entity);
NONE
(1) AbbVie (speaker's fee) (commercial entity); (2) Zambon (speaker's fee) (commercial entity); (3) Bial (speaker's fee) (commercial entity); (4) Kyowa Kirin (speaker's fee) (commercial entity)
(1) Movement Disorders, member editorial board (2006-2010) (no compensation); (2) Physiotherapy Canada,member editorial board (2007- 2016) (no compensation); (3) Tijdschrift voor Neurologie & Neurochirurgie, editor- in-chief (until 2013) (no compensation); (4) Journal of Parkinson's Disease, associate editor (2010- present) (no compensation).
NONE
NONE
NONE
Zambon (commercial entity)
NONE
NONE
NONE
(1) UCB (commercial entity); (2) AbbVie (commercial entity); (3) Verily (commercial entity).
(1) Grant of the Parkinson Society Canada?s National Research Program. Role: co-investigator. 2014 (2) Grant of Euregio (European Fund Regional Development). Role: project leader. 2014 (3) Proeftuin Zorg van de Toekomst. Grant of European Fund Regional Development (EFRO). Role: project leader. 2016. (5) Privacy en security in personalized care. Grant of Dutch province of Gelderland. Role: co-investigator. 2016
NONE
(1) Netherlands Organization for Scientific Research (non-profit entity); (2) Michael J Fox Foundation (non-profit entity); (3) Parkinson Vereniging (non-profit entity); (4) Prinses Beatrix Foundation(non-profit entity); (5) Stichting Parkinson Fonds (non-profit entity); (6) National Parkinson Foundation (non-profit entity); (7) Hersenstichting (non-profit entity)
NONE
NONE
NONE
NONE
NONE
NONE
- Daniel Weintraub, MD,
Commercial - honoraria for consultancy from Acadia, Alkahest, CHDI Foundation, Clintrex LLC, F. Hoffmann-La Roche Ltd and Sunovion Non-profit - CHDI, ADCS, ATRI
NONE
NONE
Associate Editor for Movement Disorders Journal
NONE
NONE
NONE
NONE
NONE
Licensing fees from the University of Pennsylvania for the QUIP and QUIP-RS
NONE
NONE
NINDS, P50 NS053488, Investigator, 2007-2018 NIA, U19 AG10483-22, DSMB Chair, 2013-
U. of Pennsylvania internal grant funding
Michael J. Fox Foundation for Parkinson's Research, PI,
NONE
Licensing fees from the University of Pennsylvania for licensing of Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease.
NONE
NONE
NONE
Expert testimony for defense in 2012-2017 in three lawsuits related to impulse control disorders or antipsychotic use in Parkinson's disease
- Roger A. Barker, MRCP, PhD,
NONE
NONE
NONE
Co-Editor in Chief, Journal of Neurology. Editorial Boaard of Journal of Parkinson's Disease. .
NONE
Neuroscience at a glance. 5th Edition. 2012.Wiley.
NONE
Sana; BlueRock; Nova Nordisk; FCDI; Cellino;LCT
NONE
NONE
NONE
NONE
NONE
NONE
I have recieved funding from the EU; Parkinson's UK; CHDI; Cure PD; Rosetrees trust; Michael J Fox Foundation; Wellcome Trust; MRC.
NONE
NONE
NONE
NONE
NONE
NONE
- Caroline H. Williams-Gray, MRCP, PhD,
NONE
NONE
NONE
Movement Disorders, Editorial Board Member, 2015 to present.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) RCUK/UKRI Medical Research Council, grant reference MR/R007446/1, Clinician Scientist Fellowship holder, 2018- 2023. (2) NIHR Biomedical Research Centre Award to the University of Cambridge/Cambridge University Hospitals NHS Trust, 2017-2022.
NONE
(1) Patrick Berthoud Trust (2) Raymond and Beverly Sackler Foundation (3) The Rosetrees Trust (4) Academy of Medical Sciences, UK (5) Stevenage Biosciences Catalyst (6) Addenbrooke's Charitable Trust (7) The Evelyn Trust (8) Parkinson's UK, grant reference G1507 (9) The Michael J Fox Foundation, grant reference 14912
NONE
NONE
NONE
NONE
NONE
NONE
- Bart P. van de Warrenburg, MD, PhD,
NONE
NONE
Travel stipends from the Parkinson and Movement Disorder Society and European Academy of Neurology for lectures at their international meetings, non-profit
1. Review Editor for Frontiers in Neurology (section Movement Disorders), 2011 - present 2. Member editorial board of Cerebellum & Ataxias, 2014 - present 3. Review editor for Tijdschrift voor Neurologie en Neurochirurgie, 2013-2016 All without compensation.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Bioblast Pharma
ZonMW, 9003037604 and 733051066, funding agency, 2016 - present
(1) Radboud University Medical Center, Nijmegen, the Netherlands
Hersenstichting Gossweiler Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Jacobus J. Van Hilten, MD, PhD,
NONE
Partial funding Travel/congres expences by ABBVIE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
International Parkinson Disease Foundation Van Alkemade - Keuls Foundation AbbVie
NONE
NONE
NONE
NONE
NONE
NONE
- Clemens R. Scherzer, MD,
Sanofi Scientific Advisory Committee for MOVES-PD Phase 2 Clinical Trial of Venglustat in GBA-PD
NONE
NONE
2008 - present Editorial Board Member, Biomarkers in Medicine 2011 - present Editorial Board Member, Neurogenetics
Held by Brigham & Women's Hospital: United States Letters Patent for Identification of dysregulated genes in patients with neurologic diseases, Express Mail No.: EV448719517; Date of Deposit: November 3, 2005 Held by Brigham & Women's Hospital and Sanofi Genzyme on biomarkers for proteinopathies, pending
NONE
NONE
AMGEN
NONE
C.R.S. has previously had scientific collaborations with Pfizer, Opko, Proteome Sciences.
NONE
NONE
NIH/NINDS U01NS100603 (Scherzer, Role: PI) 09/30/16-08/31/21 NIH/NIA RF1AG057331 (Role: Multi-PI: Scherzer, Feany, Fraenkel) 09/15/17-06/30/22 NIH/NINDS U01NS095736 (Scherzer, Role: PI) 09/30/16-08/31/19 NIH/NINDS U01 NS082157 (Scherzer, Role: PI) 09/30/12-07/31/18
Harvard NeuroDiscovery Center
American Parkinson Disease Association (Role: Center Director) 09/01/18-08/31/28 Michael J. Fox Foundation (Scherzer, Role: PI) 03/24/17- 03/23/19 M.E.M.O. Hoffman Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Andrew B. Singleton, PhD and
NONE
NONE
(1) 23andMe, travel payment
Serve on: Annals of Neurology Lancet Neurology Neurogenetics Neurobiology of Disease Neurodegenerative Diseases Brain Journal of Parkinson's Disease
Patent pending for panel of markers to diagnose stroke
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH Intramural funding Department of Defense, W81XWH-09-2-0128, PI, 2009-2011
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mike A. Nalls, PhD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH employee (2005-current)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Laboratory of Neurogenetics (H.I., C.B., H.L.L., F.F., D.G.H., A.B.S., M.A.N.), National Institute on Aging, National Institutes of Health, Bethesda; Data Tecnica International (H.I., M.A.N.), Glen Echo, MD; Precision Neurology Program (G.L., C.R.S.), Harvard Medical School, Brigham and Women's Hospital; Neurogenomics Laboratory (G.L., C.R.S.), Harvard Medical School, Brigham and Women's Hospital; Ann Romney Center for Neurologic Diseases (G.L., C.R.S.), Brigham and Women's Hospital, Boston, MA; The Norwegian Centre for Movement Disorders (J.M.-G., G.A.), Stavanger University Hospital; Department of Chemistry (J.M.-G., G.A.), Bioscience and Environmental Engineering, University of Stavanger, Norway; Assistance-Publique Hôpitaux de Paris (J.-C.C.), ICM, INSERM UMRS 1127, CNRS 7225, ICM, Department of Neurology and CIC Neurosciences, Pitié-Salpêtrière Hospital, Paris, France; Department of Neurology (L.P., M.T.), Oslo University Hospital, Norway; Department of Neurology (M.N., B.R.B., B.P.W.), Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Centre, Nijmegen, The Netherlands; Michael J Fox Foundation (S.J.H.), New York; Translational Genome Sciences (K.-D.H.N, K.E.), Biogen, Cambridge, MA; Department of Neurology University of Pennsylvania (J.R.), Philadelphia, PA; Department of Biostatistics and Computational Biology (S.E.), University of Rochester, NY; Department of Computer Science (F.F.), University of Illinois Urbana-Champaign; Department of Neurology (P.A.), Center for Health + Technology, University of Rochester, NY; Department of Clinical Neurosciences (K.M.S., R.W.), University of Cambridge, John van Geest Centre for Brain Repair, UK; Department of Pathology and Laboratory Medicine (V.M.V.D.), Center for Neurodegenerative Disease Research, Parelman School of Medicine at the University of Pennsylvania, Philadelphia; Genetics and Pharmacogenomics (A.G.D.-W.), Merck Research Laboratory, Boston, MA; Statistical Genetics (A.G.D.-W.), Biogen, Cambridge, MA; Institut du cerveau et de la moelle épinière ICM (A.B., F.D.); Sorbonne Université SU (A.B.); INSERM UMR1127 (A.B.), Paris, France; Department of Neurology (G.A.), Stavanger University Hospital, Norway; Preventive Neurology Unit (A.J.N.), Wolfson Institute of Preventive Medicine, Queen Mary University of London; Department of Molecular Neuroscience (A.J.N.), UCL Institute of Neurology, London, UK; Department of Neurology (O.-B.T.), Haukeland University Hospital; University of Bergen (O.-B.T.), Bergen, Norway; Department of Neurology (J.R.E.), Nottingham University NHS Trust, UK; Centre for Clinical Brain Sciences (D.P.B.), University of Edinburgh; Anne Rowling Regenerative Neurology Clinic (D.P.B.), University of Edinburgh; Usher Institute of Population Health Sciences and Informatics (D.P.B.), University of Edinburgh, Scotland; Department of Medical and Molecular Genetics (C.E.W.), Indiana University, Indianapolis; Department of Neurology (D.K.S.), Beth Israel Deaconess Medical Center; Harvard Medical School (D.K.S.), Boston; Voyager Therapeutics (B.R.), Cambridge, MA; Department of Neurology (B.R.), University of Rochester School of Medicine, NY; Institute of Clinical Medicine (M.T.), University of Oslo, Norway; German Center for Neurodegenerative Diseases-Tubingen (P.H.); HIH Tuebingen (P.H.), Germany; Department of Psychiatry (D.W.), University of Pennsylvania School of Medicine; Department of Veterans Affairs (D.W.), Philadelphia, PA; and Department of Clinical Neurosciences (R.A.B., C.H.W.-G.), University of Cambridge, UK; Department of Neurology (J.J.V.H.), Leiden University Medical Center, The Netherlands.
- Correspondence
Dr. Nalls nallsm{at}mail.nih.gov
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Daniel Friedman and Dr. Sharon Chiang